The order will support advanced research using intratracheal (IT) exposure in rats, enabling robust in vivo studies to better understand the impact of inhaled compounds.

The client is a leading university hospital in Europe, renowned for pioneering research in oncology, transplantation, cardiovascular medicine and translational sciences. The hospital treats over 50,000 inpatients and 195,000 outpatients each year and works at the forefront of integrated, interdisciplinary diagnostics and therapies. Their commitment to clinical excellence and world-leading cancer research places them among Europe’s top medical research institutions.

"This new order clearly demonstrates the trust that leading research institutions place in our unique technology and in vivo platform. We are proud that our solutions continue to support cutting-edge research in inhalation science and contribute to significant advances in preclinical studies and respiratory medicine”, comments ISABs CEO Manoush Masarrat.

This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on October 24, 2025 at 08:30.

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.